John D. Powderly

Carolina BioOncology Institute — United States

Medicine · Health Sciences

46h-index33.1kcitations310works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(157), CAR-T cell therapy research(74), Monoclonal and Polyclonal Antibodies Research(54), Immunotherapy and Immune Responses(51), Radiopharmaceutical Chemistry and Applications(39)

Publications308 total

Supplementary Figure 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Data from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 8 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
651 Imneskibart, a human monoclonal antibody (mAb) that binds IL-2 and prevents CD25 binding, + low-dose subcutaneous IL-2: phase 2 update on CPI-refractory melanoma and non-small cell lung cancer (NSCLC)
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract B016: Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)
Molecular Cancer Therapeutics·2025
Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
2025Open Access
Table 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
2025Open Access
Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
2025Open Access
page 1 of 16Next →

Frequent Co-authors

F. Stephen Hodi(19), Mario Sznol(18), David F. McDermott(17), Suzanne L. Topalian(16), David C. Smith(16), Jeffrey A. Sosman(16), Julie R. Brahmer(14), Richard D. Carvajal(13), Scott Gettinger(11), Michael B. Atkins(11), Georgia Kollia(11), Ashok Gupta(11), Philip D. Leming(10), Jon M. Wigginton(10), Harriet M. Kluger(10), Drew M. Pardoll(9), William H. Sharfman(9), Donald P. Lawrence(9), David R. Spigel(8), Charles G. Drake(8)